Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (PACTR202508611698393) titled 'A Phase I/II study of ITU512 in healthy participants and patients with sickle cell disease' on Aug. 1.
Study Type: Interventional
Study Design:
Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Central randomisation by phone/fax
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Haematological Disorders
Recruitment Status: Recruiting
Phase: Phase-1
Date of First Enrollment: 15/08/2024
Target Sample Size: 161
Countries of Recruitment:
Ghana
Ghana
Kenya
Kenya
Kenya
Uganda
To know more, visit https://pactr.samrc.ac.za/Tr...